Volpara Health Technologies

Wellington, New Zealand All New Zealand companies → — Founded 2009

Imaging AI Specialist Specialty-Focused AI

General Surgery Oncology Radiology

Oncology AI Radiology & Imaging AI

Acquired

Claim this company

Products

Volpara Imaging Software

Lunit

Oncology AI

Volpara Health Technologies Limited offers AI-powered software for personalized breast cancer screening, risk assessment, and mammography quality improvement, aiding in earlier detection and optimized clinical workflows.

See all 1 product →

About Volpara Health Technologies

Volpara Health Technologies is a leading healthcare AI company specializing in breast health, leveraging artificial intelligence to enhance the early detection of breast cancer. The company’s core offering is its Breast Health Platform, which integrates AI for clinical decision support, personalized detection strategies, and optimized program performance. This platform is clinically validated and utilized by top cancer screening centers globally, aiming to improve mammogram quality and reduce false positives.

Volpara’s software assists healthcare providers in understanding cancer risk, empowering patients in personal care decisions, and guiding recommendations for additional imaging, genetic testing, and other interventions. The AI-powered image analysis precisely quantifies breast tissue and helps technologists achieve optimal mammogram image quality, positioning, compression, and dose. The company operates on a subscription-based (SaaS) business model, offering its software to healthcare facilities and streamlining operations while providing key performance insights for continuous quality improvement.

Focus Areas

Breast cancer risk assessment volumetric breast density mammography quality AI and machine learning in breast imaging personalized breast care lung cancer screening

Business Intelligence

Technology

AI-powered software platform, cloud-native (utilizing Microsoft Azure), physics-based AI algorithms (Volpara TruDensity), Open Virtual Appliance (OVA) architecture

What Physicians Need to Know

Breast Cancer Risk Assessment

Volpara Health provides AI-powered software for personalized breast care, including automated and objective breast density assessment (VolparaDensity) and lifetime breast cancer risk scores. Their solutions integrate with risk models like Tyrer-Cuzick and BOADICEA (CanRisk) to improve accuracy. They also offer Volpara Risk Pathways, which combines clinical and lifestyle data for comprehensive, individualized risk assessments.

Volumetric Breast Density

VolparaDensity is a core product that calculates and quantifies volumetric breast density as a ratio of fibroglandular tissue and total breast volume from digital X-ray images, including tomosynthesis. This technology eliminates the subjectivity of radiologist analysis, providing a precise and objective density measure.

Mammography Quality

Volpara's AI-powered image analysis helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. Their Volpara Analytics solution leverages AI to increase mammography quality by assessing these factors, helping to reduce repeats and recalls.

AI and Machine Learning in Breast Imaging

Volpara Health specializes in leveraging artificial intelligence to enhance early detection of breast cancer. Their platform integrates AI for clinical decision support, personalized detection strategies, and optimized program performance. They combine large language models with task-specific AI to provide consistent results.

Personalized Breast Care

The company's mission is to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions.

Lung Cancer Screening

Volpara has extended its capabilities to lung cancer screening. They have a strategic agreement with Optellum, a leader in AI-enabled lung cancer diagnosis, to expand a patient's picture of cancer risk. This collaboration allows Volpara customers to access Optellum's Virtual Nodule Clinic software, which identifies the probability that a lung nodule is cancerous.

Cardiovascular Risk Assessment

Volpara is developing a solution in collaboration with Microsoft to detect and quantify breast arterial calcifications (BAC) from mammograms, which may indicate heart disease or a high risk of disease. This aims to provide a cardiac decision-support tool for radiologists.

Physician Tip

Volpara's solutions offer objective and precise measurements of breast density, reducing subjectivity and potential human error in radiologist analysis. The Volpara Scorecard product unifies essential metrics, including volumetric breast density and Volpara Density Grade, to speed up workflow and ensure critical information is factored into care decisions. The platform provides insights for personalized detection strategies and optimized program performance, helping to improve mammogram quality and reduce false positives. Additionally, the integration with risk models and genetic testing options allows for comprehensive, individualized risk assessments and tailored care plans. For lung cancer screening, access to Optellum's AI-enabled software helps identify the probability of cancerous lung nodules, aiding in earlier diagnosis and informed patient management. The company's focus on continuous quality improvement and streamlining operations can also help address staffing shortages in the industry.

Volpara's software can be deployed stand-alone or fully integrated with electronic health record (EHR) systems, mammography reporting systems, imaging hardware, and genetic laboratories. They connect to tools such as PACS, DICOM, Epic, and HL7 FHIR, allowing the AI agent to work within existing workflows. Volpara density is integrated into breast cancer risk models like Tyrer-Cuzick and BOADICEA (CanRisk). They have also collaborated with Natera, Inc. to integrate Natera's Empower Hereditary Cancer Test into their software workflow. Volpara operates 100% in the cloud on Microsoft Azure. As of 2024, Volpara Health Technologies was acquired by Lunit, and their AI breast health platforms are being integrated into Lunit's line of AI tools for breast cancer detection and a comprehensive cancer intelligence portfolio.

Products by Volpara Health Technologies

1 product in the directory

Volpara Imaging Software

Lunit

Oncology AI

What the Web Says

Volpara Health Technologies is a medical technology company specializing in AI-powered software for early breast cancer detection and risk assessment. The company's products, including volumetric density analysis and mammography quality control, are widely used in breast screening programs and are supported by extensive peer-reviewed research. Employer reviews indicate a mixed sentiment, with some praising the company culture and mission, while others express concerns about management, training, and workload.

Overall: Mixed

Strengths

AI-powered solutions for accurate and objective breast density and risk assessment.
Enhances mammography quality and radiographer performance.
Strong market leadership in breast density and image quality solutions.
Mission-driven company dedicated to fighting cancer.
Good benefits and hybrid work model.
Talented and passionate coworkers with a team atmosphere.

Limitations

Concerns about overworked and underpaid engineers.
Poor management and low morale in some departments.
Non-existent or inadequate training for new hires.
Lack of transparency and changing focus/strategy.
Challenges of working across different time zones (NZ to US).
Customer service/technical support may lack effective management.

Based on reviews from: Indeed.com, Saaskart, Retained Burnings (Mucrama), Imaging Technology News, ActiumHealth vs. Volpara Health Comparison, Reddit, Tenable®, Tracxn, Lunit

Last updated: 2026-10-24

Videos

News, demos, and interviews about Volpara Health Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Volpara Health Technologies →

View all on YouTube

Press & Coverage

Medical Device Network

Lunit to acquire Volpara Health Technologies for $193m

Medical artificial intelligence (AI) company Lunit has signed an agreement to acquire Volpara Health Technologies in a deal valued at around A$292m ($193m), expected to be completed in Q2 2024. Volpara provides software for the early detection of breast cancer and its solutions are used in over 2,000 US medical sites.

2023-12

PR Newswire

Volpara Health Announces BOADICEA Integration and Record ECR 2025 Research Presence

Volpara Health announced that its density assessment is now a validated input to the BOADICEA breast cancer risk model, integrating into two NCCN guideline-named models. Additionally, a record 21 independent abstracts featuring Lunit and Volpara solutions were presented at ECR 2025.

2025-03

Lunit

Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence

Volpara Health Technologies will now operate under the Lunit brand, unifying their strengths in breast health and AI innovation following Lunit's 2024 acquisition. This integration creates a comprehensive ecosystem for cancer intelligence, serving over 10,000 healthcare providers globally.

2025-11

PR Newswire

Volpara Health Surpasses 300 Peer-Reviewed Papers

Volpara Health, a Lunit company, reached a milestone with the publication of its 300th peer-reviewed scientific paper using Volpara results, underscoring its commitment to evidence-based AI technologies for breast cancer detection. Two recent studies highlight the benefits of Volpara's AI technology in improving radiologist performance and identifying women at higher risk for missed cancers.

2024-10

MobiHealthNews

Lunit, Volpara Health announce a consolidated ecosystem for cancer care

Lunit and Volpara Health are combining forces to develop a comprehensive ecosystem for early cancer detection, risk prediction, and improved clinical workflows. This collaboration integrates Volpara's AI breast health platforms with Lunit's AI tools, aiming to transform cancer care.

2024-12

ASX

Volpara Health Technologies Limited (ASX: VHT) – Removal from Official List

Volpara Health Technologies Limited was removed from the Official List of the ASX on May 22, 2024, following the implementation of the scheme of arrangement for its acquisition by Lunit Inc.

2024-05

RSNA Press Room

Volpara Health breast density and mammography quality software highlighted in new peer-reviewed research

Volpara Health Technologies was featured in two peer-reviewed studies at RSNA 2023, highlighting its AI-powered software for breast density and mammography quality. The research showcased advancements in breast radiation dose modeling and improved radiographer performance using Volpara Analytics.

2023-12

Imaging Technology News

Lunit Issues Update on Acquisition of Volpara with Initial Approval Secured from New Zealand High Court

Lunit announced that the High Court of New Zealand granted an initial order for its acquisition of Volpara Health Technologies, and all necessary consents under New Zealand's Overseas Investment Act have been secured. Volpara shareholders were invited to vote on the proposed acquisition on April 12, 2024.

2024-03

Frequently Asked Questions

How does Volpara Health Technologies' software improve breast cancer risk assessment and personalized breast care?

Volpara's software integrates volumetric breast density, patient-specific risk factors, and AI-powered analytics to provide a more accurate and personalized breast cancer risk assessment. This allows for tailored screening recommendations and individualized patient management strategies, moving beyond traditional, less precise methods.

What role does Volpara's technology play in assessing volumetric breast density and enhancing mammography quality?

Volpara's solutions objectively measure volumetric breast density, which is a crucial risk factor for breast cancer and can mask tumors on mammograms. Additionally, their software provides real-time feedback on mammography positioning and compression, helping to improve image quality and consistency across screenings.

How does Volpara incorporate AI and machine learning into its breast imaging products?

Volpara leverages AI and machine learning algorithms to analyze vast amounts of imaging data, identify subtle patterns, and assist radiologists in detecting potential abnormalities. This technology also powers their risk assessment models and helps optimize mammography quality control, leading to more efficient and accurate interpretations.

Does Volpara Health Technologies offer solutions for lung cancer screening, and what are the key features of those products?

Yes, Volpara offers lung cancer screening solutions, including VolparaLung, which provides automated lung nodule management and tracking. This helps healthcare providers efficiently manage their lung cancer screening programs, ensuring timely follow-ups and compliance with guidelines.

What is Volpara's approach to data compliance, pricing models, and customer support for their products?

Volpara prioritizes data security and compliance with healthcare regulations like HIPAA and GDPR. Their pricing models are typically subscription-based, offering flexibility for different practice sizes. They provide comprehensive customer support, including implementation assistance, training, and ongoing technical support to ensure optimal product utilization.

What are Volpara's key partnerships, and how do they contribute to the company's stability and product development?

Volpara collaborates with leading imaging equipment manufacturers, academic institutions, and research organizations. These partnerships are crucial for integrating their software with various mammography platforms, validating their technology through clinical studies, and staying at the forefront of breast imaging innovation, contributing to their long-term stability.

How does Volpara's technology assist in meeting regulatory compliance for breast density reporting and quality metrics?

Volpara's software automates breast density assessment, providing objective and consistent measurements that help healthcare facilities comply with state and federal breast density reporting mandates. It also tracks key quality metrics for mammography, aiding in accreditation and continuous quality improvement initiatives.

Related Companies

Suggest an Edit → | Report an issue